HeraMED Limited (1I4) - Net Assets
Based on the latest financial reports, HeraMED Limited (1I4) has net assets worth €931.03K EUR (≈ $1.09 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.49 Million ≈ $1.74 Million USD) and total liabilities (€559.96K ≈ $654.65K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is HeraMED Limited's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €931.03K |
| % of Total Assets | 62.44% |
| Annual Growth Rate | -23.64% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1330.57 |
HeraMED Limited - Net Assets Trend (2018–2025)
This chart illustrates how HeraMED Limited's net assets have evolved over time, based on quarterly financial data. Check 1I4 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for HeraMED Limited (2018–2025)
The table below shows the annual net assets of HeraMED Limited from 2018 to 2025. For live valuation and market cap data, see market value of HeraMED Limited.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €931.03K ≈ $1.09 Million |
-66.40% |
| 2024-12-31 | €2.77 Million ≈ $3.24 Million |
+3502.08% |
| 2023-12-31 | €76.93K ≈ $89.94K |
-98.17% |
| 2022-12-31 | €4.21 Million ≈ $4.92 Million |
+4068.84% |
| 2021-12-31 | €-105.98K ≈ $-123.91K |
-104.09% |
| 2020-12-31 | €2.59 Million ≈ $3.03 Million |
-23.88% |
| 2019-12-31 | €3.41 Million ≈ $3.98 Million |
-44.57% |
| 2018-12-31 | €6.15 Million ≈ $7.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HeraMED Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3702189900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €45.11 Million | 4845.69% |
| Total Equity | €931.03K | 100.00% |
HeraMED Limited Competitors by Market Cap
The table below lists competitors of HeraMED Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RDE, Inc.
NASDAQ:GIFT
|
$28.31 Million |
|
Daesung Private Equity Inc
KQ:027830
|
$28.33 Million |
|
Colorpak Indonesia Tbk
JK:CLPI
|
$28.33 Million |
|
Samchuly Bicycle Co. Ltd
KQ:024950
|
$28.34 Million |
|
AJ Bell plc
LSE:AJB
|
$28.29 Million |
|
Sunson Textile Manufacturer
JK:SSTM
|
$28.27 Million |
|
Aveng Ltd
JSE:AEG
|
$28.25 Million |
|
BPL Limited
NSE:BPL
|
$28.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HeraMED Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,771,109 to 931,029, a change of -1,840,080 (-66.4%).
- Net loss of 4,131,627 reduced equity.
- New share issuances of 1,979,409 increased equity.
- Other factors increased equity by 312,138.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.13 Million | -443.77% |
| Share Issuances | €1.98 Million | +212.6% |
| Other Changes | €312.14K | +33.53% |
| Total Change | €- | -66.40% |
Book Value vs Market Value Analysis
This analysis compares HeraMED Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.31x to 25.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | €0.07 | €0.02 | x |
| 2019-12-31 | €0.03 | €0.02 | x |
| 2020-12-31 | €0.02 | €0.02 | x |
| 2021-12-31 | €0.00 | €0.02 | x |
| 2022-12-31 | €0.02 | €0.02 | x |
| 2023-12-31 | €0.00 | €0.02 | x |
| 2024-12-31 | €0.00 | €0.02 | x |
| 2025-12-31 | €0.00 | €0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HeraMED Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -443.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1408.29%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.60x
- Recent ROE (-443.77%) is below the historical average (-270.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -86.78% | -4880.82% | 0.01x | 1.27x | €-5.95 Million |
| 2019 | -131.03% | -2152.08% | 0.04x | 1.51x | €-4.81 Million |
| 2020 | -168.10% | -8500.28% | 0.01x | 1.60x | €-4.62 Million |
| 2021 | 0.00% | -6588.20% | 0.02x | 0.00x | €-5.70 Million |
| 2022 | -170.56% | -2229.48% | 0.05x | 1.45x | €-7.59 Million |
| 2023 | -964.81% | -1117.60% | 0.21x | 4.08x | €-6.68 Million |
| 2024 | -198.14% | -1507.04% | 0.08x | 1.62x | €-5.77 Million |
| 2025 | -443.77% | -1408.29% | 0.20x | 1.60x | €-4.22 Million |
Industry Comparison
This section compares HeraMED Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $43,087,734,998
- Average return on equity (ROE) among peers: -21.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HeraMED Limited (1I4) | €931.03K | -86.78% | 0.60x | $28.30 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $16.74 Billion | 1.48% | 0.47x | $158.24K |
| BIORETEC OY (0TN) | $8.23 Million | -46.03% | 0.29x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $683.20 Million | 13.73% | 0.12x | $711.77 Million |
| Medtronic PLC (2M6) | $15.97 Billion | 19.39% | 0.91x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $2.81 Billion | -73.53% | 0.02x | $328.75 Million |
| AVITA Medical Inc (51KB) | $72.40 Million | -58.05% | 0.14x | $172.49 Million |
| BRAINCOOL AB (5YL) | $116.23 Million | -39.24% | 0.15x | $21.56 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.33 Billion | -20.20% | 0.10x | $107.57 Million |
About HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a digital maternity and women's health platform that focuses on improving clinical outcomes while supporting more effic… Read more